Introduction
An airway response to bronchoconstrictor agonists at doses that would have little or no effect in normal human subjects is a characteristic feature of people with asthma (1) (2) (3) (4) . Further, it has been demonstrated, in a variety of experimental systems, that autocoids and proteases produced by mast cells (5, 6) have the capacity to increase bronchial reactivity; these include platelet activating factor (PAF)' (7), leukotriene E4 (LTE4) (8, 9) , thromboxane A2 (TxA2) ( 10, 1), prostaglandin F2, (PGF2,) ( 12) , and tryptase ( 13) . Because the administration of mast cell products can transiently influence airway responsiveness, it has been proposed that mast cell activation may importantly contribute to the bronchial hyperreactivity observed in asthmatic subjects (14) (15) (16) . On the other hand, the molecules that have been implicated as potential inducers ofairway hyperreactivity can also be produced by other cell types (15) (16) (17) (18) (19) . As a result, the importance of the mast cell, as a specific source of mediators capable of promoting airway hyperresponsiveness, has been difficult to assess.
To evaluate directly whether mast cell activation influences airway responsiveness in vivo, we studied genetically mast celldeficient mice, their congenic normal mice, and mast cell-deficient mutant mice whose deficiency had been repaired by adoptively transferring populations of mast cells. We reasoned that, if mast cells represent a crucial source of mediators that are released by IgE-dependent mechanisms and enhance airway responsiveness, infusion oflow doses ofanti-IgE before agonist administration would enhance responsiveness only in mice that possess mast cells. Our results clearly indicate that mast cell activation enhances airway responsiveness to methacholine in the mouse.
Methods

Animals
We studied WBB6F1 + / + normal and WBB6F, W/ WV mast cell-deficient mice (Dr. Warren Frost, Bozeman, Montana) and WCB6F1 + / + normal and WCB6F1 S//Sd mast cell-deficient mice (Jackson Laboratories, Bar Harbor, ME), 3-6 mo ofage. Both the WBB6F1 W/WV and the WCB6F1 S11S1d mutant mice are profoundly deficient in mast cells in all anatomical tissues (20) (21) (22) . They possess < 0.5% of the normal numbers of cutaneous mast cells and no mast cells are detectable by histology in any other tissues, including the tracheobronchial system and pulmonary parenchyma. All mice were maintained in a facility for viral antibody free mice and fed standard diets until time of study. The study protocols were approved by the (20) ; these mice were designated +/+BM -. W/W' mice. This reconstitution method has been shown to provide normal numbers of mast cells in tracheobronchial and other tissues of W/ Wv recipients, and also repairs the anemia of these mice (20) (21) (22) 
Pulmonary function measurements
Lung conductance (GL) was monitored in anesthetized, tracheotomized, ventilated mice as previously described (27) . Agonists were administered via a silastic catheter tied into a jugular vein. Plethysmograph pressure (from which changes in lung volume were derived) and transpulmonary pressure were transduced by differential pressure transducers (Celesco, Canoga Park, CA). The outputs were amplified and digitized, then analyzed using a computerized cross-correlation method ' (28) for which signals from 8-10 consecutive breaths were stored and averaged. The GL peak response to each agonist dose was expressed as percentage of the baseline value obtained immediately before that dose of agonist.
Histology
Tracheobronchial and cutaneous tissues were fixed in 2.0% paraformaldehyde, 2.5% glutaraldehyde, and 0.025% CaCl2 in 0.1 M sodium cacodylate buffer, pH 7.3, and stored overnight at 40C. They were then washed in 0.1 M sodium cacodylate buffer, pH 7.3, and stored in the same buffer at 4°C until processing into 1 um Epon-embedded, Giemsa-stained sections (29) . The sections were examined at x400 for assessment of mast cell numbers in tissues of all mice and for quantification of extent of mast cell degranulation in tissues of + / +, + / +BM -> W/ WV, and BMCMC --W/ wv mice (30, 31) . Mast cells were scored as normal (< 10% of cytoplasmic granules exhibiting fusion, staining alterations, or extrusion from the cell), moderately degranulated ( 10-50% of granules altered as above) or extensively degranulated (> 50% of granules altered as above). 
Protocols
Statistical analysis
To help assess whether responses to methacholine might have been influenced by differences in airway caliber between anti-IgE-or salinepretreated mice, we used a Student's t test (two-tailed) to compare GL values (ml * s-' cm H20-'1) obtained 20 min after pretreatment with anti-IgE or saline. We also used ANOVA to compare, in anti-IgE-vs. saline-pretreated mice, the entire series of baseline values beginning with the value obtained 20 min after pretreatment and including all the baseline values obtained just before each subsequent dose ofmethacholine.
We primarily used ANOVA to compare agonist dose response (expressed as percent of baseline) curves in the various groups of mice. Further, for each mouse dose-response curve, we also calculated the ED50GL (Ag/ kg) by linear interpolation as the dose of agonist required to obtain a 50% decrease in GL. Geometric means of these values and the arithmetic means of the maximal reductions in GL were compared by unpaired two-tailed Student's t tests. Extent of mast cell degranulation was compared by X2 analysis. Differences with a P value of < 0.05 were considered significant. The data in the figures are presented as mean±SEM.
Results
Mch
Normal vs. mast cell-deficient mice not treated with anti-IgE. When their responses were compared by analysis of variance, we found that the WBB6F, -+ / + mice were significantly (P < 0.0001), albeit slightly, more responsive to methacholine than were the congenic mast cell-deficient W/W" littermates ( Anti-IgE-vs. saline-pretreated mast cell-reconstituted mice. In + / + BM -* W/Wv mice, there was no significant difference in the baseline GL values obtained 20 min after treatment with anti-IgE vs. saline (Fig. 3, legend) +/+BM --W/WV mice (P < 0.0001, ANOVA, Fig. 3 (Fig. 4, legend) . The series of baseline GL values obtained before each dose ofMch was significantly higher for the anti-IgE-treated BMCMC -* W/ WV mice than for the matched saline-treated group (P < 0.02, ANOVA). Anti-IgE also significantly enhanced the GL response to Mch (P < 0.0001, ANOVA, Fig. 4 (Table II) revealed a much greater degree of mast cell degranulation in the anti-IgE-pretreated mice than in the saline-pretreated mice (P < 0.0001 for each comparison). Mast cells were not detectable in any tissues from four ofsix anti-IgE-treated BMCMC --W/ Wv mice; the rare mast cells detected in the other two mice all exhibited moderate to extensive degranulation. Although the differences for each group were not significant, tracheal mast cell numbers/mm2 were lower in anti-IgE-treated mice of all groups compared with respective saline treated control groups (Table  I) . These latter findings together with the results obtained in previous studies of mice which have undergone extensive mast cell activation (31, 32) and saline-pretreated groups was highly significant (P < 0.0001, X2).
compared to their saline treated control groups. Finally, if the increased Mch responsiveness observed after the injection of anti-IgE was simply the result ofa mechanical effect ofresidual constriction, the responsiveness to 5-HT would have been similarly increased, which was not the case (Fig. 5) .
The initial finding that anti-IgE treatment enhanced Mch responsiveness in normal mice could have been explained by the activation of FcLR-bearing cell types other than the mast cell. However, W/WV mice are not defective in basophils ( 35 ) , the only effector cell other than the mast cell which expresses the high-affinity FcfR on its surface. Yet we observed no increase in the Mch responsiveness of W/ Wv mice pretreated with anti-IgE. In addition, we used two mast cell reconstitution approaches to demonstrate that it was the mast cell deficiency ofthe W/ W" or Sl/Sld mice, not other consequences of their mutations, which was responsible for their inability to exhibit increased airway responsiveness to Mch challenge after injection with anti-IgE.
We (Fig. 3) (27) and it is possible that anti-IgIE-induced mast cell degranulation led to release of quantities of 5-HT in the lung which were sufficient to reduce pulmonary responsiveness to exogenous 5-HT. Since mice of this genetic background do not develop bronchoconstrictor responses to other mediators, including histamine, LTC4, PGF2a, substance P, and PAF (27), we could not determine whether the anti-IgE-treated mice exhibited generalized pulmonary hyperresponsiveness.
It has been shown by others that IgE-mediated antigenic stimulation enhances cholinergic bronchial reactivity (36) (37) (38) (39) . Although the mechanism of enhanced cholinergic responsiveness due to mast cell activation is not known, it is known that a number of mast cell products (5-13) can enhance airway responses. Of particular interest is the observation that mastocytoma cell culture supernatants or purified mast cell tryptase can induce a dose-related increase in canine bronchial responsiveness in vitro ( 13) . The in vitro enhancement of bronchial responsiveness by mast cell products was observed for agonists such as histamine, 5-HT, and potassium chloride, mediators which contract airway smooth muscle by a mechanism predominantly involving membrane potential-dependent Ca2t ransport, but not for acetylcholine, which contracts airway smooth muscle by a mechanism independent of calcium channels. The differences in agonist responses following putative mast cell and IgE dependent priming of canine tissues in vitro and of mice in vivo may be related to species differences, to the difference between a constant tissue bath exposure vs. a bolus injection, or to differences between large airway responses and those of the more peripheral small airways. The differences in results may also reflect important differences between in vitro studies, in which tissues are examined after separation from their blood supply and connection with the central nervous system, and in vivo studies, in which airway smooth muscle cell function can be influenced by other cell types such as airway epithelial cells, as well as by factors dependent on an intact vasculature and nerve supply.
Mast cell products other than proteases may also contribute to the enhanced bronchial reactivity observed after IgE-dependent mast cell activation. Both in vitro-derived mouse mast cells (40) (41) (42) (43) and freshly isolated mouse peritoneal mast cells (41, 42) can produce tumor necrosis factor-a in response to IgE-dependent activation. Several lines of evidence indicate that tumor necrosis factor-a can contribute to airway hyperreactivity in the rat in vivo (44) . In addition to exerting potentially important direct effects on bronchial reactivity, mast cell-derived cytokines might influence airway reactivity indirectly, by promoting the recruitment and/or modulating the function of other cell types which have effects in the airways. For example, eosinophils represent a prominent feature of the pathology of asthma (45, 46) , eosinophils produce mediators which can influence bronchial reactivity (45) , and mast cellderived cytokines may contribute to the recruitment ofeosinophils to sites of mast cell activation (47) .
However, it is unlikely that any of the results obtained in our experiments were eosinophil dependent. In this study we examined responsiveness to methacholine or 5-HT 20 min after inducing IgE-dependent mast cell activation in immunologically naive mice. This is too short an interval for significant mast cell-dependent leukocyte infiltration to occur (42) . Moreover, histological analysis of these mice indicated that neither the anti-IgE-treated nor the saline-treated mice exhibited eosinophils or other leukocytic infiltrates in their respiratory tissues.
T lymphocytes may also contribute to the pathology associated with chronic allergic asthma (46) . However, an extensive body of data (reviewed in references 21 and 32) indicates that W/ WV or SlI/Sd mice exhibit no T cell deficiencies. These animals also express no impairment in their ability to mount an IgE response (reviewed in reference 32). This evidence, taken together with the fact that we studied acute rather than chronic pulmonary responses, indicates that the differences in bronchial reactivity we observed in mast cell-deficient as opposed to congenic normal mice probably did not reflect abnormalities of T cell function in the mutant animals.
In summary, our data provide strong evidence that mast cell activation can promote airway hyperreactivity, and that this effect can be produced by activation of a relatively small number of mast cells. Although the mast cell mediators responsible for this effect in the mouse have not been defined, it is tempting to speculate that ongoing IgE-mediated activation of human mast cells may contribute significantly to the airway hyperreactivity that characterizes the asthmatic state.
